Helicobacter pylori treatment in Turkey: Current status and rational treatment options

TOZUN, Ayşe Nurdan; KAPLAN, Mustafa; DÜZENLİ, Tolga; TANOĞLU, Alpaslan

doi:10.14744/nci.2019.62558

Helicobacter pylori treatment in Turkey: Current status and rational treatment options

Mustafa KAPLAN, (Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi, Gastroenteroloji Bölümü, İstanbul, Türkiye)

Alpaslan TANOĞLU, (Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi, Gastroenteroloji Bölümü, İstanbul, Türkiye)

Tolga DÜZENLİ, (Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi, Gastroenteroloji Bölümü, İstanbul, Türkiye)

Ayşe Nurdan TOZUN (Acıbadem Üniversitesi, Gastroenteroloji Bölümü, İstanbul, Türkiye)

İstanbul Kuzey Klinikleri

18 3

Yıl: 2020 Cilt: 7 Sayı: 1 Sayfa Aralığı: 87 - 94 Metin Dili: İngilizce DOI: 10.14744/nci.2019.62558 İndeks Tarihi: 17-09-2020

Helicobacter pylori treatment in Turkey: Current status and rational treatment options

Öz:

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, manycountries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however,current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence,cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs torevise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori.This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations forrational therapeutic considerations for the eradication of the bacterium.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299–304.
2. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the ¹³C-Urea breath test. BMC Public Health 2013;13:1215.
3. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273–5.
4. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698–709.
5. Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter 2017;22.
6. Losurdo G, Leandro G, Principi M, Giorgio F, Montenegro L, Sorrentino C, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by ‘geographical weighting’. Int J Clin Pract 2015;69:1112–20.
7. Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017;23:525–32.
8. Bayındır Bilman F, Özdemir M, Baysal B, Güzel Kurtoğlu M. Prevalence of H. pylori in gastric biopsy specimen in the southeastern region of Turkey. J Infect Dev Ctries 2016;10:1177–82.
9. Uyanikoglu A, Coskun M, Binici DN, Kibar YI, Tay A, Ozturk Y. Evaluation of gastroscopic and pathologic results in Erzurum region. Türkiye Klinikleri J Gastroenterohepatol 2011;18:70–4.
10. Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2016;21 Suppl 1:3–7.
11. Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, et al. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol 2016;16:80.
12. Matsuhisa T. The trend of Helicobacter pylori infection rate: time, region, race and strain. Helicobacter Res 2015;19:469–80.
13. Anand PS, Nandakumar K, Shenoy KT. Are dental plaque, poor oral hygiene, and periodontal disease associated with Helicobacter pylori infection? J Periodontol 2006;77:692–8.
14. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015;6:183–98.
15. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353–67.
16. Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer 2017;20:3–7.
17. Calhan T, Kahraman R, Sahin A, Senates E, Doganay HL, Kanat E, et al. Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study. Helicobacter 2013;18:378–83.
18. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
19. Gisbert JP, Luna M, Gómez B, Herrerías JM, Monés J, Castro-Fernández M, et al. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. Aliment Pharmacol Ther 2006;23:713–9.
20. Erdoğan FA, Abacı K, Serin E, Özer B, İçer MO. Are first-line Helicobacter pylori eradication therapies alarming? Akademik Gastroenteroloji Dergisi 2009;8:59–62.
21. Aydın Y, Nazlıgül Y, Yeniova AÖ, Kefeli A, Şimşek G, Saçıkara M, et al. The efficacy of levofloxacin based triple therapy for first-line Helicobacter pylori eradication Dicle Med J 2011;38:197–201.
22. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35–44.
23. Başyiğit S, Kefeli A, Sapmaz F, Doğan Ö, Yeniova AÖ. Evaluating the efficacy and safety of levofloxacin containing hybrid treatment protocol in the first-line therapy of Helicobacter pylori eradication. Akademik Gastroenteroloji Dergisi 2016;15:97–101.
24. Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395–403.
25. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027–30.
26. Ormeci A, Emrence Z, Baran B, Soyer OM, Gokturk S, Evirgen S, et al. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism? Eur Rev Med Pharmacol Sci 2016;20:1795–7.
27. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006;44:297–302.
28. Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensivemetabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2016;27:408–14.
29. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016;151:51–69.
30. Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori. J Clin Pharm Ther 2012;37:282–5.
31. Demirci H, Uygun İlikhan S, Öztürk K, Üstündağ Y, Kurt Ö, Bilici M, et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. Turk J Gastroenterol 2015;26:456–60.
32. Itskoviz D, Boltin D, Leibovitzh H, Tsadok Perets T, Comaneshter D, Cohen A, et al. Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig Liver Dis 2017;49:764–8.
33. Cekin AH, Şahintürk Y, Akbay Harmandar F, Uyar S, Yolcular BO, Çekin Y. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. Turk J Gastroenterol 2017;28:3–11
34. Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, et al. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Dig Dis Sci 2017;62:1580–9.
35. Kekilli M, Onal IK, Ocal S, Dogan Z, Tanoglu A. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol 2016;22:366–9.

APA	KAPLAN M, TANOĞLU A, DÜZENLİ T, TOZUN A (2020). Helicobacter pylori treatment in Turkey: Current status and rational treatment options. , 87 - 94. 10.14744/nci.2019.62558
Chicago	KAPLAN Mustafa,TANOĞLU Alpaslan,DÜZENLİ Tolga,TOZUN Ayşe Nurdan Helicobacter pylori treatment in Turkey: Current status and rational treatment options. (2020): 87 - 94. 10.14744/nci.2019.62558
MLA	KAPLAN Mustafa,TANOĞLU Alpaslan,DÜZENLİ Tolga,TOZUN Ayşe Nurdan Helicobacter pylori treatment in Turkey: Current status and rational treatment options. , 2020, ss.87 - 94. 10.14744/nci.2019.62558
AMA	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A Helicobacter pylori treatment in Turkey: Current status and rational treatment options. . 2020; 87 - 94. 10.14744/nci.2019.62558
Vancouver	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A Helicobacter pylori treatment in Turkey: Current status and rational treatment options. . 2020; 87 - 94. 10.14744/nci.2019.62558
IEEE	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A "Helicobacter pylori treatment in Turkey: Current status and rational treatment options." , ss.87 - 94, 2020. 10.14744/nci.2019.62558
ISNAD	KAPLAN, Mustafa vd. "Helicobacter pylori treatment in Turkey: Current status and rational treatment options". (2020), 87-94. https://doi.org/10.14744/nci.2019.62558

APA	KAPLAN M, TANOĞLU A, DÜZENLİ T, TOZUN A (2020). Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri, 7(1), 87 - 94. 10.14744/nci.2019.62558
Chicago	KAPLAN Mustafa,TANOĞLU Alpaslan,DÜZENLİ Tolga,TOZUN Ayşe Nurdan Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri 7, no.1 (2020): 87 - 94. 10.14744/nci.2019.62558
MLA	KAPLAN Mustafa,TANOĞLU Alpaslan,DÜZENLİ Tolga,TOZUN Ayşe Nurdan Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri, vol.7, no.1, 2020, ss.87 - 94. 10.14744/nci.2019.62558
AMA	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri. 2020; 7(1): 87 - 94. 10.14744/nci.2019.62558
Vancouver	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri. 2020; 7(1): 87 - 94. 10.14744/nci.2019.62558
IEEE	KAPLAN M,TANOĞLU A,DÜZENLİ T,TOZUN A "Helicobacter pylori treatment in Turkey: Current status and rational treatment options." İstanbul Kuzey Klinikleri, 7, ss.87 - 94, 2020. 10.14744/nci.2019.62558
ISNAD	KAPLAN, Mustafa vd. "Helicobacter pylori treatment in Turkey: Current status and rational treatment options". İstanbul Kuzey Klinikleri 7/1 (2020), 87-94. https://doi.org/10.14744/nci.2019.62558